¼¿ï´ëÇб³º´¿ø 2019 ´ëÇÑÇ÷¾×ÇÐȸ AML/MDS¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2019-05-25±³À°ÀÏÀÚ : 2019-05-25
±³À°Àå¼Ò : ¼¿ï´ëÇб³º´¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ ¼¼ºÈ¯ Ȧ
±³À°ÁÖÁ¦ :
2019 ´ëÇÑÇ÷¾×ÇÐȸ AML/MDS¿¬±¸È¸ ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : AML/MDS¿¬±¸È¸
´ã´çÀÚ : Á¤¼¼¿µ
¿¬¶ôó : 02-533-1408
À̸ÞÀÏ :
amlmds.wp@gmail.com ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-25 ¼¼ºÈ¯ Ȧ 10:00~10:30 Venetoclax for myeloid malignancies ±è¼º¿ë(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 05-25 ¼¼ºÈ¯ Ȧ 10:30~11:00 FLT3 inhibitor for myeloid malignancies ¾öÁöÀº(ÇѾçÀÇ´ë)
±³À°½Ã°£ 05-25 ¼¼ºÈ¯ Ȧ 11:00~11:30 IDH1/2 inhibitor for myeloid malignancies ¼ÛÀÍÂù(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 05-25 ¼¼ºÈ¯ Ȧ 11:30~12:00 Myeloid neoplasms with germline DDX41 mutation À̼º¿í(°í·ÁÀÇ´ë)
±³À°½Ã°£ 05-25 ¼¼ºÈ¯ Ȧ 13:20~13:30 Are clonal cells circulating in the peripheral blood of myelodysplastic syndrome? Ȳ»ó¹Ì(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-25 ¼¼ºÈ¯ Ȧ 13:30~13:40 Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients ¹Ú½Çºñ¾Æ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-25 ¼¼ºÈ¯ Ȧ 13:55~14:05 Comparison of survival outcome between donor types or stem cell sources for childhood acute myeloid leukemia after allogenic hematopoietic stem cell transplantation ½É¿¹Áö(°è¸íÀÇ´ë)
±³À°½Ã°£ 05-25 ¼¼ºÈ¯ Ȧ 14:05~14:15 Next-generation sequencing-based post-transplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse ¹®ÁØÈ£(°æºÏÀÇ´ë)
±³À°½Ã°£ 05-25 ¼¼ºÈ¯ Ȧ 14:45~14:55 ¿¬±¸È¸ ¿¬±¸ Àü¹Ý ÁøÇà »óȲ update º¸°í ±èÇõ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 05-25 ¼¼ºÈ¯ Ȧ 14:55~15:05 °üÇØÀ¯µµÇ×¾ÏÈÇпä¹ý¿¡ ÀûÇÕÇÏÁö ¾ÊÀº °í·ÉÀÇ Çѱ¹ ±Þ¼º°ñ¼ö¼º¹éÇ÷º´ ȯÀÚ¿¡¼ °üÇØÀ¯µµÄ¡·á·Î¼ÀÇ µ¥½ÃŸºó¿¡ ´ëÇÑ ÀüÇâÀû ¿¬±¸ ÀÓ¼º³²(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 05-25 ¼¼ºÈ¯ Ȧ 15:05~15:15 Àç¹ßºÒÀÀ ±Þ¼º°ñ¼ö¼º¹éÇ÷º´ ȯÀÚ¿¡¼ azacitidine Ä¡·á (SAPPIRE-A) È«ÁؽÄ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-25 ¼¼ºÈ¯ Ȧ 15:15~15:25 Áø´Ü ½Ã NGS ±â¹Ý BCOR/BCORL1 µ¹¿¬º¯ÀÌ ´Üµ¶ ¾ç¼º ¶Ç´Â Ÿ µ¹¿¬º¯À̵é°úÀÇ º¹ÇÕ ¾ç¼º ¼Ò°ß¿¡ µû¸¥ Á¤»óÇÙÇü-AML ȯÀÚÀÇ ÀÓ»ó ¼ºÀû¿¡ ´ëÇÑ ÈÄÇ⠺м® ¿¬±¸ Á¤ÁØ¿ø(¿¬¼¼ÀÇ´ë)